Business news

    Genetic Technologies (ASX:GTG) publishes evidence of its breast cancer risk test

    Article Image

    Genetic Technologies (ASX:GTG) has published a research paper in the peer-reviewed journal Cancer Prevention Research that demonstrates the utility of its geneType Breast Cancer Risk Assessment Test.

    The study compared geneType to a gold-standard model and found that geneType not only put more women into an increased risk category, but also demonstrated women in this category developed breast cancer at a higher incidence.

    The study is the third paper accepted for publication in the last six months that highlights the utility of geneType.

    Genetic Technologies says it's hoping the research will help them gain traction with US Payers to initiate a pilot study.

     

    Disclaimer

    Grafa is not a financial advisor. You should seek independent, legal, financial, taxation or other advice that relates to your unique circumstances. Grafa is not liable for any loss caused, whether due to negligence or otherwise arising from the use of, or reliance on the information provided directly or indirectly by use of this platform.

    Publisher
    Grafa